Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Vertex Pharmaceuticals Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Turnover Ratios
Inventory turnover 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62
Receivables turnover 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01
Payables turnover 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75
Working capital turnover 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99
Average No. Days
Average inventory processing period 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139
Add: Average receivable collection period 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52
Operating cycle 406 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191
Less: Average payables payment period 102 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77
Cash conversion cycle 304 274 242 229 211 190 166 154 137 131 112 150 120 122 119 144 139 137 114

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The analysis of the provided quarterly financial ratios and periods over time reveals several notable trends related to operational efficiency and working capital management.

Inventory Turnover
The inventory turnover ratio displayed a gradual decline from 2.62 in March 2020 to 1.06 by June 2025, indicating a slower inventory movement and potentially increased inventory holding. Correspondingly, the average inventory processing period increased significantly from 139 days to 345 days over the same period, reinforcing the observation of slower inventory clearance.
Receivables Turnover
The receivables turnover ratio exhibited moderate fluctuations, generally ranging between about 5.95 and 7.19. There was a slight downward trend overall towards the end of the timeline. The average receivable collection period correspondingly remained fairly stable, oscillating between 51 and 64 days, with a mild tendency towards longer collection times in later periods, suggesting some pressure on accounts receivable collection efficiency.
Payables Turnover
The payables turnover ratio showed significant variability, ranging from 3.13 to 8.23, with no consistent upward or downward trend. The average payables payment period also fluctuated widely, spanning from 44 days to as high as 117 days. This volatility indicates changing payment practices to suppliers, with periods of quicker payments interspersed with periods of extended payment terms.
Working Capital Turnover
The working capital turnover ratio remained relatively stable around 0.9 to 1.03 during the early periods, then experienced a notable increase starting around March 2024, peaking near 1.92 before slightly moderating. This suggests improving efficiency in utilizing working capital to generate sales or revenue in later periods.
Operating Cycle
The operating cycle lengthened from 191 days to 406 days, indicating that the combined duration of inventory holding and receivables collection extended considerably. This lengthening reflects slower asset turnover and possibly increased capital tied up in operating processes.
Cash Conversion Cycle
The cash conversion cycle generally increased from 114 days to 304 days, with fluctuations that mirror changes in inventory and receivables periods, partially offset by variations in payables payment periods. An increasing cash conversion cycle suggests the company's cash is tied up longer in the operational process before being converted back into cash inflows.

In summary, the data illustrate a trend toward slower inventory turnover and longer operating and cash conversion cycles, denoting elongated working capital cycles over the analyzed timeframe. Receivables collection efficiency showed minor deterioration, while payables payment practices varied considerably without a clear trend. Improvement in working capital turnover ratios in recent periods could indicate enhanced utilization of working capital despite longer operating cycles, which may point to strategic shifts or changes in business operations impacting liquidity management.


Turnover Ratios


Average No. Days


Inventory Turnover

Vertex Pharmaceuticals Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Cost of sales 407,500 363,000 423,400 392,600 371,900 342,600 368,000 318,700 308,600 266,900 283,300 289,400 261,800 245,800 247,387 236,512 227,972 192,329 203,101 186,182 184,520 162,497
Inventories 1,499,300 1,359,700 1,205,400 1,079,800 914,600 813,100 738,800 688,700 603,500 535,100 460,600 388,200 367,700 338,900 353,100 333,456 321,620 298,863 280,777 245,460 219,218 187,087
Short-term Activity Ratio
Inventory turnover1 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96 5.58 5.76 5.45 5.40 4.65
Amgen Inc. 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48 1.58 1.53 1.53 1.53 1.58
Bristol-Myers Squibb Co. 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55 4.74 4.85 5.01 5.61 5.68
Danaher Corp. 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87 4.16 4.06 4.28 4.34 4.28
Eli Lilly & Co. 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93 1.88 1.79 1.80 1.68 1.38
Gilead Sciences Inc. 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50 4.08 3.21 2.99 2.79 2.72
Johnson & Johnson 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77 2.87 2.86 2.91 2.86 3.04
Merck & Co. Inc. 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74 2.29 2.73 2.79 2.40 2.45
Pfizer Inc. 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67 3.40 2.78 1.80 1.28 1.08
Regeneron Pharmaceuticals Inc. 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27 1.25 0.88 0.82 0.56 0.58
Thermo Fisher Scientific Inc. 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87 3.88 3.90 4.03 4.01 4.02

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Inventory turnover = (Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024 + Cost of salesQ3 2024) ÷ Inventories
= (407,500 + 363,000 + 423,400 + 392,600) ÷ 1,499,300 = 1.06

2 Click competitor name to see calculations.


Cost of Sales
The cost of sales shows a general upward trend over the analyzed period. Starting from around $162.5 million in the first quarter of 2020, it increased steadily with some fluctuations, reaching a peak of approximately $423.4 million in the first half of 2025. Notably, there was a significant rise during 2023 and 2024, indicating higher expenses related to goods sold or produced.
Inventories
Inventories exhibited consistent growth throughout the entire period. Beginning at roughly $187.1 million in early 2020, inventories more than doubled by mid-2024, reaching approximately $1.35 billion by June 2025. This steady accumulation suggests increasing stock levels, which could imply inventory buildup possibly due to higher production or slower sales turnover.
Inventory Turnover Ratio
The inventory turnover ratio, which measures how efficiently inventory is managed, demonstrates a declining trend. Starting from around 2.62 in late 2020, it gradually decreased to about 1.06 by mid-2025. This reduction indicates that inventories are being sold or used up less frequently over time, pointing to potentially slower inventory movement or increasing inventory holding periods.
Summary of Trends and Insights
The combination of rising cost of sales and rapidly increasing inventories coupled with a declining inventory turnover ratio suggests that while the company is incurring higher costs and accumulating more stock, the efficiency in converting inventory into sales is diminishing. This pattern may be indicative of expanding operations or production capacity, but also hints at possible challenges in inventory management or demand forecasting that could affect cash flow and profitability if not addressed.

Receivables Turnover

Vertex Pharmaceuticals Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Revenues 2,964,700 2,770,200 2,912,000 2,771,900 2,645,600 2,690,600 2,517,700 2,483,500 2,493,200 2,374,800 2,302,700 2,334,300 2,196,200 2,097,500 2,072,561 1,984,164 1,793,370 1,724,305 1,627,820 1,538,271 1,524,485 1,515,107
Accounts receivable, net 1,893,500 1,805,100 1,609,400 1,750,600 1,656,100 1,793,200 1,563,400 1,538,700 1,556,200 1,547,800 1,442,200 1,385,200 1,332,900 1,292,800 1,136,800 1,100,372 929,142 977,551 885,352 791,917 791,768 845,269
Short-term Activity Ratio
Receivables turnover1 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29 5.63 5.94 5.42 5.24 5.19
Amgen Inc. 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81 4.96 5.11 5.39 5.41 5.36
Danaher Corp. 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87 6.36 6.69 6.51 6.28 5.51
Eli Lilly & Co. 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64 4.24 4.69 4.58 4.56 4.18
Gilead Sciences Inc. 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18 6.01 5.95 6.34 6.43 4.98
Johnson & Johnson 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08 6.14 6.13 6.00 5.64 6.08
Merck & Co. Inc. 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49 5.28 5.56 6.00 5.65 6.11
Pfizer Inc. 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99 7.08 5.81 5.23 4.70 5.28
Regeneron Pharmaceuticals Inc. 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41 2.66 2.48 1.77 2.20 2.07
Thermo Fisher Scientific Inc. 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21 4.92 7.03 6.99 6.46 5.61

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Receivables turnover = (RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024 + RevenuesQ3 2024) ÷ Accounts receivable, net
= (2,964,700 + 2,770,200 + 2,912,000 + 2,771,900) ÷ 1,893,500 = 6.03

2 Click competitor name to see calculations.


The revenue figures demonstrate a consistent upward trend from March 31, 2020, through June 30, 2025. Starting at approximately 1.52 billion US dollars in the first quarter of 2020, revenues increase almost steadily each quarter, reaching close to 3 billion US dollars by the second quarter of 2025. Although minor fluctuations are observable in some quarters, the overall growth trajectory is positive, indicating sustained business expansion or successful market penetration over the observed period.

Accounts receivable, net, also show an increasing trend in absolute terms, growing from around 845 million US dollars in the first quarter of 2020 to nearly 1.89 billion US dollars by the second quarter of 2025. This increase appears somewhat aligned with the revenue growth, as higher sales volumes generally result in greater outstanding receivables. However, the rate of growth in accounts receivable is variable, with some quarters experiencing sharper increases than others, suggesting changing credit terms, customer payment behaviors, or collection efforts throughout the periods.

Receivables Turnover Ratio
This ratio, which measures how efficiently the company collects its receivables, exhibits some variability but remains within a range approximately between 5.68 and 7.19 over the period.
Beginning at about 7.01 in September 2020, the turnover ratios fluctuate, showing occasional declines followed by recoveries. The ratio tends to hover around the mid-6 range for most quarters, with a few dips below 6.0, notably in mid-2023 and early 2024, which could indicate slower receivable collection or extended payment periods during those times.
Overall, the receivables turnover rate suggests relatively stable but somewhat fluctuating efficiency in collecting receivables, despite the growing absolute values of accounts receivable. This mix of increasing receivable balances alongside a moderately steady turnover ratio points to the company managing its credit and collections reasonably well, even as sales and credit exposure increase.

In summary, the data reveals sustained revenue growth accompanied by rising accounts receivable, with the efficiency of receivables collection remaining generally stable but with periodic fluctuations. The increasing receivables imply higher credit sales or extended credit durations, while the turnover ratio suggests that collection processes are effective enough to maintain relatively consistent performance over the multiple-year span.


Payables Turnover

Vertex Pharmaceuticals Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Cost of sales 407,500 363,000 423,400 392,600 371,900 342,600 368,000 318,700 308,600 266,900 283,300 289,400 261,800 245,800 247,387 236,512 227,972 192,329 203,101 186,182 184,520 162,497
Accounts payable 442,300 445,000 413,000 395,800 327,900 351,400 364,900 375,900 363,000 323,200 303,900 126,900 198,000 173,600 195,000 127,863 127,534 127,839 155,139 107,786 101,451 100,703
Short-term Activity Ratio
Payables turnover1 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65 4.72 5.41 4.92 4.40 4.33
Bristol-Myers Squibb Co. 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25 3.37 3.89 2.97 3.69 4.34
Danaher Corp. 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04 4.48 5.20 5.54 5.29 4.79
Eli Lilly & Co. 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24 4.38 4.46 4.30 3.75 3.41
Gilead Sciences Inc. 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43 9.36 9.18 8.70 8.71 5.42
Johnson & Johnson 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26 2.70 3.32 3.38 3.34 2.99
Merck & Co. Inc. 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25 2.96 4.54 3.93 3.81 3.37
Pfizer Inc. 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66 5.53 5.11 3.72 2.68 2.02
Regeneron Pharmaceuticals Inc. 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39 4.32 4.23 3.42 2.23 2.36
Thermo Fisher Scientific Inc. 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96 6.83 8.31 8.88 8.12 7.45

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Payables turnover = (Cost of salesQ2 2025 + Cost of salesQ1 2025 + Cost of salesQ4 2024 + Cost of salesQ3 2024) ÷ Accounts payable
= (407,500 + 363,000 + 423,400 + 392,600) ÷ 442,300 = 3.59

2 Click competitor name to see calculations.


The cost of sales demonstrates a general increasing trend throughout the analyzed periods, starting from approximately $162.5 million in March 2020 and rising to a peak around $423.4 million in June 2025, though with some fluctuations. Notably, there was a substantial rise from December 2023 to June 2024, followed by a slight dip before rising again, indicating a possible seasonal or cyclical variation in costs or production scale.

Accounts payable also show fluctuations but generally follow an upward trajectory, increasing from about $100.7 million in March 2020 to approximately $442.3 million by June 2025. A significant jump is observed between December 2022 and March 2023, where payables increased sharply from around $303.9 million to over $323.2 million and continued an upward trend thereafter. This increase in payables may indicate either extended credit terms or higher purchasing activity.

Payables turnover ratio data is available from September 2020 onwards and reveals some variability. The ratio peaked at 8.23 in December 2022, indicating rapid payment to suppliers relative to cost of sales during that quarter. Subsequently, the turnover generally declined, fluctuating between approximately 3.13 and 4.27 from December 2023 to June 2025. This trend suggests a lengthening of the accounts payable period or slower payment pace in more recent quarters.

Cost of Sales
Consistent overall growth with a few fluctuations, indicating expanding operations or rising costs over time.
Accounts Payable
Increased notably, particularly from late 2022 onward, which may imply changes in supplier credit terms or purchasing volume.
Payables Turnover
Displayed a peak in late 2022, followed by a moderate decline, suggesting a shift towards longer payment periods in recent quarters.

In summary, the financial data indicates that while the company’s cost of sales has grown steadily, the rise in accounts payable and the declining payables turnover ratio in recent periods could reflect changes in working capital management strategy, possibly aiming to conserve cash or benefit from extended supplier payment terms. Monitoring these trends will be important for assessing liquidity and supplier relationships going forward.


Working Capital Turnover

Vertex Pharmaceuticals Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in thousands)
Current assets 10,427,900 10,008,800 9,596,400 9,804,100 8,941,600 13,288,700 14,144,200 14,695,800 13,872,900 12,965,700 13,234,800 12,271,000 11,503,500 10,361,300 9,560,600 8,852,540 8,457,514 8,539,307 8,133,379 7,458,456 6,694,320 5,446,400
Less: Current liabilities 4,138,400 3,783,200 3,564,600 3,973,100 3,547,200 3,795,900 3,547,400 3,599,400 3,352,100 3,026,200 2,742,100 2,609,300 2,556,200 2,180,200 2,142,000 1,914,264 1,836,448 1,944,050 1,877,533 2,004,026 1,798,640 1,538,750
Working capital 6,289,500 6,225,600 6,031,800 5,831,000 5,394,400 9,492,800 10,596,800 11,096,400 10,520,800 9,939,500 10,492,700 9,661,700 8,947,300 8,181,100 7,418,600 6,938,276 6,621,066 6,595,257 6,255,846 5,454,430 4,895,680 3,907,650
 
Revenues 2,964,700 2,770,200 2,912,000 2,771,900 2,645,600 2,690,600 2,517,700 2,483,500 2,493,200 2,374,800 2,302,700 2,334,300 2,196,200 2,097,500 2,072,561 1,984,164 1,793,370 1,724,305 1,627,820 1,538,271 1,524,485 1,515,107
Short-term Activity Ratio
Working capital turnover1 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97 1.02 1.03 1.01 0.97 0.99
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. 130.12
Amgen Inc. 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34 3.37 2.55 5.35 2.84 2.55
Bristol-Myers Squibb Co. 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24 3.95 4.43 4.24 4.25 3.72
Danaher Corp. 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91 8.40 7.98 3.12 3.45 3.48
Eli Lilly & Co. 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19 8.33 6.73 12.14 5.21 4.93
Gilead Sciences Inc. 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68 8.54 7.25 7.09 7.06 5.30
Johnson & Johnson 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57 5.95 5.97 5.93 7.26 9.44
Merck & Co. Inc. 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09 7.62 6.51 6.97 84.97 109.83
Pfizer Inc. 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10 4.78 4.29 4.21 3.60 4.58
Regeneron Pharmaceuticals Inc. 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46 1.59 1.35 1.29 1.35 1.20
Thermo Fisher Scientific Inc. 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13 5.87 2.30 3.10 3.36 2.76

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Working capital turnover = (RevenuesQ2 2025 + RevenuesQ1 2025 + RevenuesQ4 2024 + RevenuesQ3 2024) ÷ Working capital
= (2,964,700 + 2,770,200 + 2,912,000 + 2,771,900) ÷ 6,289,500 = 1.82

2 Click competitor name to see calculations.


The financial data over the observed periods reveals several notable trends concerning working capital, revenues, and the working capital turnover ratio.

Working Capital
The working capital generally exhibited an increasing trend from March 2020 through December 2022, rising from approximately 3.9 billion USD to nearly 10.5 billion USD. A peak is observed in Q4 2022 at around 10.5 billion USD. However, starting in Q1 2023, working capital shows some fluctuation, with values oscillating between roughly 9.5 billion USD and 11.1 billion USD until Q4 2023. From Q1 2024 onward, there is a marked decline in working capital to around 5.4 billion USD by mid-2024, after which a slight recovery occurs, but it remains below previous peak levels through mid-2025.
Revenues
Revenues reveal a consistent upward trajectory between Q1 2020 and Q4 2022, climbing from about 1.5 billion USD to over 2.3 billion USD, indicating steady growth. The revenue values remain relatively stable but show modest increases post-2022, fluctuating between 2.3 billion USD and nearly 3 billion USD through mid-2025. Despite minor quarterly variations, the overall revenue trend maintains a positive growth pattern.
Working Capital Turnover Ratio
The working capital turnover ratio appears only from Q3 2020 onward. Early in its appearance, the ratio hovers around 1.0, indicating that revenues and working capital are growing at similar rates. From late 2021 to early 2023, the ratio decreases gradually, dipping to about 0.85 at its lowest point, suggesting that working capital grows faster than revenues during this period. Starting from Q1 2024, the ratio exhibits a sharp increase, peaking near 1.92 in mid-2024, which coincides with the aforementioned decline in working capital and moderate revenue growth. This elevated turnover ratio persists through mid-2025, signifying more efficient use of working capital relative to revenues during this timeframe.

In summary, the data shows a substantial buildup of working capital up until the end of 2022, with revenues increasing steadily throughout the entire period. However, working capital decreases sharply starting in 2024, while revenues continue to grow modestly. This shifting dynamic is reflected in the rising working capital turnover ratio, indicating improved efficiency in working capital utilization in relation to revenues in the most recent periods analyzed.


Average Inventory Processing Period

Vertex Pharmaceuticals Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Inventory turnover 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83 2.56 2.58 2.52 2.56 2.62
Short-term Activity Ratio (no. days)
Average inventory processing period1 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 107 98 90 89 75 75 73 77 85 81 75 66 73 74 65 63 67 68 79
Amgen Inc. 194 195 199 209 257 321 411 259 265 279 281 272 260 247 231 239 239 239 231
Bristol-Myers Squibb Co. 70 69 67 102 98 99 91 84 83 93 84 76 79 80 77 75 73 65 64
Danaher Corp. 101 96 88 101 102 98 96 104 102 104 91 96 98 94 88 90 85 84 85
Eli Lilly & Co. 435 379 329 349 316 312 298 261 267 268 237 196 204 189 194 204 203 217 265
Gilead Sciences Inc. 108 103 100 101 110 102 100 105 106 102 97 78 81 81 89 114 122 131 134
Johnson & Johnson 168 163 165 169 166 158 154 149 164 155 147 136 136 132 127 128 125 128 120
Merck & Co. Inc. 162 150 147 149 153 151 144 139 137 134 124 118 119 133 159 134 131 152 149
Pfizer Inc. 239 229 222 219 178 170 149 138 158 119 95 101 100 99 107 131 203 284 338
Regeneron Pharmaceuticals Inc. 570 582 572 573 562 553 519 508 532 549 562 440 379 287 292 415 445 653 625
Thermo Fisher Scientific Inc. 80 76 72 79 76 74 72 76 79 79 79 85 91 94 94 94 91 91 91

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.06 = 345

2 Click competitor name to see calculations.


The inventory-related metrics demonstrate a discernible trend over the observed periods, reflecting changes in the efficiency of inventory management.

Inventory turnover ratio
Beginning from March 2020 through June 2020, data is unavailable; however, starting March 2021, the ratio remained relatively stable around 2.5 to 2.6 until the first quarter of 2022. Post that period, there is a gradual but consistent decline in the ratio through to June 2025, dropping from 2.35 to as low as 1.06 by mid-2025. This decline suggests a decreasing rate at which inventory is sold and replaced, indicating potential challenges in inventory management efficiency or changes in sales volume relative to inventory levels.
Average inventory processing period (number of days)
This metric conversely shows an increasing trend over the same duration. From March 2021 onwards, the processing period fluctuated in the 130 to 145 days range until early 2022, after which it started to rise steadily. It increased from 156 days in the first quarter of 2022 to 345 days by March 2025. This increasing duration indicates that inventory remains on hand for longer periods, reinforcing the observations from the declining turnover ratio and pointing towards a slowdown in inventory movement.

Overall, the data indicates a progressive slowdown in inventory turnover, with inventory items taking longer to process through the system. This may imply overstocking, reduced demand, or operational inefficiencies affecting inventory flow. Monitoring these trends is critical for managing working capital and maintaining operational effectiveness.


Average Receivable Collection Period

Vertex Pharmaceuticals Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Receivables turnover 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15 6.66 6.48 7.19 6.56 7.01
Short-term Activity Ratio (no. days)
Average receivable collection period1 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 79 79 71 75 78 80 75 76 75 74 71 68 72 69 65 61 67 70 70
Amgen Inc. 95 91 77 86 86 88 99 88 84 84 82 79 79 76 74 71 68 67 68
Danaher Corp. 54 54 54 54 51 52 60 59 55 53 57 51 54 53 57 55 56 58 66
Eli Lilly & Co. 97 90 89 92 103 80 97 93 93 99 88 84 80 79 86 78 80 80 87
Gilead Sciences Inc. 61 56 56 59 62 62 63 64 57 57 65 59 55 51 61 61 58 57 73
Johnson & Johnson 72 65 61 67 67 64 64 62 68 65 62 60 62 60 59 60 61 65 60
Merck & Co. Inc. 68 62 58 66 68 68 63 64 69 66 58 59 62 66 69 66 61 65 60
Pfizer Inc. 69 69 66 87 74 72 69 58 48 48 40 59 55 52 52 63 70 78 69
Regeneron Pharmaceuticals Inc. 144 144 160 161 155 146 158 156 148 151 160 148 132 107 137 147 206 166 177
Thermo Fisher Scientific Inc. 73 72 70 71 68 68 70 70 67 66 66 63 66 70 74 52 52 56 65

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.03 = 61

2 Click competitor name to see calculations.


Receivables Turnover Ratio
The receivables turnover ratio exhibits moderate fluctuations over the analyzed periods, ranging roughly between 5.95 and 7.19. The initial recorded value of 7.01 saw a slight decline to 6.56 in the next quarter and rebounded to a peak of 7.19 shortly thereafter. Through 2021 and 2022, the ratio fluctuated mostly in a narrow band between 6.15 and 6.66, indicating stable but slightly varying efficiency in collecting receivables. In more recent quarters, the ratio displayed a mild downward trend with occasional recoveries, dropping to as low as 5.68 at one point, before modestly rising again. Overall, the turnover ratio trends suggest consistent collection activity with some seasonal or operational variations affecting receivables turnover.
Average Receivable Collection Period (Days)
The average collection period inversely correlates with the receivables turnover ratio and consistently remains within a range of approximately 51 to 64 days. An initial value of 52 days increased to 56, then decreased back to 51 early on, indicating some initial volatility. For the majority of the timeframe, the collection period oscillated between 55 and low 60s days, suggesting a relatively stable timeframe for collecting receivables. Notable is the gradual increase to 64 days during one quarter, which may indicate a temporary slowdown in collections or extended credit terms. Generally, despite minor fluctuations, the average collection period remained stable with minor increases possibly reflecting changes in credit policy or customer payment behavior.
Overall Trend and Insights
The data reflects stability in the company's receivables management, with the turnovers and collection periods oscillating within tight ranges without drastic deterioration or improvement. The presence of some variability suggests responsiveness to operational factors or market conditions. No sharp or sustained trends indicate significant changes in credit policy or collection efficiency. Maintaining such consistency in receivable performance is beneficial for managing cash flow predictability and indicates effective credit management practices over the observed periods.

Operating Cycle

Vertex Pharmaceuticals Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Average inventory processing period 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139
Average receivable collection period 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52
Short-term Activity Ratio
Operating cycle1 406 379 340 327 296 286 272 271 252 238 215 194 193 188 198 198 196 198 191
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 186 177 161 164 153 155 148 153 160 155 146 134 145 143 130 124 134 138 149
Amgen Inc. 289 286 276 295 343 409 510 347 349 363 363 351 339 323 305 310 307 306 299
Danaher Corp. 155 150 142 155 153 150 156 163 157 157 148 147 152 147 145 145 141 142 151
Eli Lilly & Co. 532 469 418 441 419 392 395 354 360 367 325 280 284 268 280 282 283 297 352
Gilead Sciences Inc. 169 159 156 160 172 164 163 169 163 159 162 137 136 132 150 175 180 188 207
Johnson & Johnson 240 228 226 236 233 222 218 211 232 220 209 196 198 192 186 188 186 193 180
Merck & Co. Inc. 230 212 205 215 221 219 207 203 206 200 182 177 181 199 228 200 192 217 209
Pfizer Inc. 308 298 288 306 252 242 218 196 206 167 135 160 155 151 159 194 273 362 407
Regeneron Pharmaceuticals Inc. 714 726 732 734 717 699 677 664 680 700 722 588 511 394 429 562 651 819 802
Thermo Fisher Scientific Inc. 153 148 142 150 144 142 142 146 146 145 145 148 157 164 168 146 143 147 156

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 345 + 61 = 406

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period demonstrates a clear upward trend over the observed timeline starting from March 31, 2021. Initially, it remains relatively stable around the 139 to 145 days range. However, from March 31, 2023, there is a noticeable increase, with the period extending progressively from 156 days to as high as 345 days by June 30, 2025. This indicates a growing duration to process inventory, which could suggest potential challenges in inventory management or slower turnover rates over time.
Average Receivable Collection Period
The average receivable collection period shows moderate fluctuations across the quarters. It ranges mostly between 51 and 64 days with no consistent trend of increase or decrease. There are minor peaks and troughs, such as a peak at 64 days on June 30, 2024, and a low of 51 days on September 30, 2020. Overall, the receivable collection period remains relatively stable, indicating consistent efficiency or terms in collecting receivables over the reporting periods.
Operating Cycle
The operating cycle, which reflects the total time taken from inventory processing through receivable collection, follows the pattern seen in the inventory processing period. It gradually increases from 191 days as of March 31, 2021, to 406 days by June 30, 2025. The steady rise, particularly accelerating from early 2023 onwards, mirrors the elongation of the inventory processing period. This extension of the operating cycle suggests that the company is experiencing longer working capital cycles, potentially tying up more resources in inventory and receivables, which might impact liquidity and operational efficiency.

Average Payables Payment Period

Vertex Pharmaceuticals Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Payables turnover 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52 4.64 6.73 6.35 5.99 4.75
Short-term Activity Ratio (no. days)
Average payables payment period1 102 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 89 70 54 61 73 60 69 70 64 73 90 69 72 78 77 67 74 83 84
Bristol-Myers Squibb Co. 140 104 94 106 120 117 111 97 108 114 109 96 107 112 108 94 123 99 84
Danaher Corp. 65 66 66 60 63 62 65 65 63 64 67 65 73 72 82 70 66 69 76
Eli Lilly & Co. 161 140 140 135 142 127 134 130 138 119 106 86 87 70 83 82 85 97 107
Gilead Sciences Inc. 34 43 49 49 29 34 31 37 40 41 58 33 31 32 39 40 42 42 67
Johnson & Johnson 119 123 137 120 121 113 132 111 133 120 137 118 116 112 135 110 108 109 122
Merck & Co. Inc. 95 92 98 86 83 81 89 80 80 84 89 71 75 86 123 80 93 96 108
Pfizer Inc. 106 110 115 99 79 87 98 72 93 76 72 66 59 55 66 71 98 136 181
Regeneron Pharmaceuticals Inc. 129 129 146 94 110 137 122 106 116 136 138 98 91 68 84 86 107 164 155
Thermo Fisher Scientific Inc. 43 44 45 38 37 37 41 35 34 39 48 37 41 46 53 44 41 45 49

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.59 = 102

2 Click competitor name to see calculations.


The payables turnover ratio exhibits notable volatility over the observed quarters. Initially, the ratio increased from 4.75 to a peak of 6.73, indicating accelerated payment of payables by the company during this period. Subsequently, a significant decline occurred, with the ratio dropping to as low as 3.13 in the quarter ending December 31, 2023. This downward trend suggests a slower rate of payables turnover. More recently, there is a moderate recovery, with the ratio rising to approximately 3.59 by June 30, 2025, yet it remains below earlier peak levels.

Correspondingly, the average payables payment period demonstrates an inverse movement relative to the payables turnover ratio, as expected. The payment period shortened from 77 days to 54 days during the initial quarters, indicative of quicker settlements with suppliers. Following this, there was a marked increase in the payment days, reaching a maximum of 117 days by December 31, 2023. This reflects a lengthening of the company's payment cycle. In later periods, the payment duration gradually decreased to around 102 days by mid-2025 but still signifies extended payment terms compared to the earliest quarters.

Payables Turnover Ratio
The ratio peaked in late 2020 and then declined sharply through 2023, before experiencing a mild recovery.
Average Payables Payment Period
The number of days to pay suppliers decreased initially, then increased substantially, peaking in late 2023, followed by a slight decline but remaining elevated.
Relationship Between Metrics
There is an inverse correlation between the two metrics, consistent with standard financial principles: higher turnover corresponds with shorter payment periods, and vice versa.
Implications
The initial improvement in payables turnover suggested strengthening cash outflow efficiency, while the subsequent decline and lengthening payment periods could indicate strategic supplier payment deferral or temporary liquidity management measures. The recent stabilization may reflect an adjustment to new operating conditions or financial policies.

Cash Conversion Cycle

Vertex Pharmaceuticals Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data
Average inventory processing period 345 320 287 267 238 222 214 213 192 177 156 136 135 129 143 142 145 142 139
Average receivable collection period 61 59 53 60 58 64 58 58 60 61 59 58 58 59 55 56 51 56 52
Average payables payment period 102 105 98 98 85 96 106 117 115 107 103 44 73 66 79 54 57 61 77
Short-term Activity Ratio
Cash conversion cycle1 304 274 242 229 211 190 166 154 137 131 112 150 120 122 119 144 139 137 114
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 200 216 222 234 270 349 441 277 285 290 273 282 267 245 228 243 233 223 215
Danaher Corp. 90 84 76 95 90 88 91 98 94 93 81 82 79 75 63 75 75 73 75
Eli Lilly & Co. 371 329 278 306 277 265 261 224 222 248 219 194 197 198 197 200 198 200 245
Gilead Sciences Inc. 135 116 107 111 143 130 132 132 123 118 104 104 105 100 111 135 138 146 140
Johnson & Johnson 121 105 89 116 112 109 86 100 99 100 72 78 82 80 51 78 78 84 58
Merck & Co. Inc. 135 120 107 129 138 138 118 123 126 116 93 106 106 113 105 120 99 121 101
Pfizer Inc. 202 188 173 207 173 155 120 124 113 91 63 94 96 96 93 123 175 226 226
Regeneron Pharmaceuticals Inc. 585 597 586 640 607 562 555 558 564 564 584 490 420 326 345 476 544 655 647
Thermo Fisher Scientific Inc. 110 104 97 112 107 105 101 111 112 106 97 111 116 118 115 102 102 102 107

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 345 + 61102 = 304

2 Click competitor name to see calculations.


Average Inventory Processing Period
The average inventory processing period demonstrates a general upward trend from March 2021 onward. Starting at 139 days, it gradually increases over subsequent quarters, reaching 345 days by June 2025. This indicates a lengthening time for inventory turnover, suggesting either slower movement of stock or changes in inventory management practices.
Average Receivable Collection Period
The average receivable collection period fluctuates but largely stays within a narrow range between 51 and 64 days. There is no clear upward or downward trend, indicating that the company's efficiency in collecting receivables remains relatively stable over the analyzed periods.
Average Payables Payment Period
The average payables payment period shows more volatility. It begins around 79 days in March 2021, decreases to a low of 44 days by December 2021, then increases steadily to peak at around 117 days in December 2023 before declining slightly to around 102 days by June 2025. This suggests variability in the company's payment timing to suppliers, including periods of faster payment and others with extended payment timings.
Cash Conversion Cycle
The cash conversion cycle exhibits a notable increasing trend, starting around 114 days in March 2021 and rising consistently to reach approximately 304 days by June 2025. This increase is driven primarily by the rising inventory processing period and the fluctuating but generally stable receivable periods combined with an initially decreasing then rising payable period. The elongation of the cash conversion cycle may imply higher working capital requirements and reduced liquidity efficiency.